MX2022010781A - Vacuna contra el virus sars-cov-2 con adyuvante cpg. - Google Patents

Vacuna contra el virus sars-cov-2 con adyuvante cpg.

Info

Publication number
MX2022010781A
MX2022010781A MX2022010781A MX2022010781A MX2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A
Authority
MX
Mexico
Prior art keywords
adjuvanted
cov
sars
cpg
virus vaccine
Prior art date
Application number
MX2022010781A
Other languages
English (en)
Spanish (es)
Inventor
Robert Schlegl
Christoph Reinisch
Robert S Janssen
Andreas Meinke
Jürgen Heindl-Wruss
John D Campbell
David Novack
Michael Möhlen
Christian Taucher
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Priority claimed from PCT/IB2021/052858 external-priority patent/WO2021176434A1/en
Publication of MX2022010781A publication Critical patent/MX2022010781A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022010781A 2020-04-06 2021-04-06 Vacuna contra el virus sars-cov-2 con adyuvante cpg. MX2022010781A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20168324 2020-04-06
EP20202124 2020-10-15
EP20211936 2020-12-04
EP21154645 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
EP21160933 2021-03-05
PCT/IB2021/052858 WO2021176434A1 (en) 2020-03-01 2021-04-06 Cpg-adjuvanted sars-cov-2 virus vaccine

Publications (1)

Publication Number Publication Date
MX2022010781A true MX2022010781A (es) 2023-03-09

Family

ID=83887208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010781A MX2022010781A (es) 2020-04-06 2021-04-06 Vacuna contra el virus sars-cov-2 con adyuvante cpg.

Country Status (4)

Country Link
KR (1) KR20230005814A (ko)
CN (1) CN115666633A (ko)
CA (1) CA3168783A1 (ko)
MX (1) MX2022010781A (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432437A (zh) * 2022-01-07 2022-05-06 广东粤港澳大湾区国家纳米科技创新研究院 四氧化三锰颗粒在制备疫苗佐剂中的应用
CN116983401A (zh) * 2023-06-29 2023-11-03 贝湾生物科技有限公司 基于sars1病毒的新冠加强免疫疫苗

Also Published As

Publication number Publication date
KR20230005814A (ko) 2023-01-10
CN115666633A (zh) 2023-01-31
CA3168783A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
MX2018007627A (es) Vacuna contra el virus del zika.
WO2021204825A3 (en) INACTIVATED SARS-CoV-2 VIRUS VACCINE
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
MX344596B (es) Vacuna de subunidad recombinante del virus del dengue.
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EA202090967A1 (ru) Стабильные составы вакцин, включающих, в частности, живой аттенуированный рекомбинантный флавивирус, и процесс их приготовления
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
SG10201811190SA (en) Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
EA201690057A1 (ru) Остеопонтин молока млекопитающих для повышения иммунологической реактивности
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
MX2022012447A (es) Vacuna inactivada contra el virus sars-cov-2.
EA202190914A1 (ru) Иммуногенные композиции
PH12016502529A1 (en) Influenza vaccine nasal vaccination system
MX2023004016A (es) Vacunas de poliepitopo del herpesvirus.
MX2022004869A (es) Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma.
AR121752A1 (es) VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
MX2023000097A (es) Adyuvantes de vacunas y metodos de sintetizacion y uso de estos.
WO2024068265A3 (en) Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
ZA202300164B (en) Modified alphavirus for use as covid-19 vaccine
MX2022001430A (es) Formulaciones de vacuna contra chikungu?a.
WO2022256637A3 (en) Synthetic dna vaccine immunogenic improvements
EA202090386A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ГЕТЕРОЛОГИЧНЫХ репРНК ИММУНИЗАЦИЙ
AR105134A1 (es) Vacunas contra la influenza con coincidencia antigénica